Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410464 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| SCHEMBL1270440 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| Hydrochloric Acid SCHEMBL12465553 | 0.98 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| SCHEMBL23568185 | 0.94 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| SCHEMBL18371474 | 0.92 | ALDH1A1 (0.45) | ALDH1A1HSD17B10KDM4ETSHRKMT2A | |
| SCHEMBL22779188 | 0.90 | ALDH1A1 (0.44) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| SCHEMBL23476610 | 0.90 | KDM4E (0.47) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR | |
| SCHEMBL23646017 | 0.87 | HSD17B10 (0.62) | ALDH1A1HSD17B10KDM4ETSHRSLC6A9 | |
| SCHEMBL8742080 | 0.87 | HSD17B10 (0.62) | ALDH1A1HSD17B10KDM4ETSHRSLC6A9 | |
| SCHEMBL17029294 | 0.87 | ALDH1A1 (0.42) | ALDH1A1HSD17B10KDM4EHSD11B1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021123013-A1 | SMART DRUG DELIVERY SYSTEM AND PHARMACEUTICAL KIT FOR DUAL NUCLEAR MEDICAL CYTOTOXIC THERANOSTICS | Johannes Gutenberg-Universität Mainz (DE) | 2021-06-24 | — | — | WO | disclosed |
| US-10793533-B2 | Dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-10-06 | — | — | US | disclosed |
| US-20200017453-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-01-16 | — | — | US | disclosed |
| EP-3564218-A1 | METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID | Viwit Pharmaceutical Co., Ltd. (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-20190209713-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING S.P.A. (IT) | 2019-07-11 | — | — | US | disclosed |
| US-20190209713-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING S.P.A. (IT) | 2019-07-11 | — | — | US | disclosed |
| US-10328162-B1 | CEST systems exhibiting a concentration independent responsiveness | BRACCO IMAGING S.P.A. (IT) | 2019-06-25 | — | — | US | disclosed |
| US-10328162-B1 | CEST systems exhibiting a concentration independent responsiveness | BRACCO IMAGING S.P.A. (IT) | 2019-06-25 | — | — | US | disclosed |
| US-10232060-B2 | CEST systems exhibiting a concentration independent responsiveness | BRACCO IMAGING S.P.A. (IT) | 2019-03-19 | — | — | US | disclosed |
| US-10232060-B2 | CEST systems exhibiting a concentration independent responsiveness | BRACCO IMAGING S.P.A. (IT) | 2019-03-19 | — | — | US | disclosed |
| EP-2635311-B1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING SPA (IT) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017098044-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| EP-2635311-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | Bracco Imaging S.p.A (IT) | 2013-09-11 | — | — | EP | disclosed |
| US-20130195768-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| US-20130195768-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING S.P.A. (IT) | 2013-08-01 | — | — | US | disclosed |
| WO-2012059576-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | BRACCO IMAGING SPA (IT) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209713-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | NCS1, CERS2, LSS | ALDH1A1 4721/4885HSD17B10 3140/4885KDM4E 3440/4885 |
| US-10232060-B2 | CEST systems exhibiting a concentration independent responsiveness | NCS1, CES1, BRS3 | ALDH1A1 4722/4885HSD17B10 2905/4885KDM4E 4355/4885 |
| US-10793533-B2 | Dimeric contrast agents | CALCOCO2, SLC39A14, NOD2 | ALDH1A1 4705/4885HSD17B10 4707/4885KDM4E 4112/4885 |
| US-20130195768-A1 | CEST SYSTEMS EXHIBITING A CONCENTRATION INDEPENDENT RESPONSIVENESS | NCS1, CERS2, LSS | ALDH1A1 4721/4885HSD17B10 3140/4885KDM4E 3440/4885 |
| US-20200017453-A1 | DIMERIC CONTRAST AGENTS | CALCOCO2, SLC39A14, NOD2 | ALDH1A1 4705/4885HSD17B10 4707/4885KDM4E 4112/4885 |
| US-10328162-B1 | CEST systems exhibiting a concentration independent responsiveness | NCS1, CERS2, LSS | ALDH1A1 4721/4885HSD17B10 3140/4885KDM4E 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.